With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
Looking for a way improve biochemical failure rates in prostate cancer?
Slow down. For years we've known dose escalation equals disease-free survival escalation. But is it time to get our hands dirty? The ASCENDE-RT trial published in this month’s Red Journal reports that men randomized to a low-dose rate brachytherapy boost had half the rates of biochemical failure than their external beam boost companions—21% less at 9 years to be exact—when used concurrent and sequential to 8 months of ADT. But don't throw on your scrubs just yet. There were no differences in overall survival (shocking, we know), and a companion study shows these men have triple the rates of GU toxicity at 5 years.